A Phase 1 interventional study of enzalutamide and anastrozole in Breast Cancer, sponsored by Pfizer. Completed at 17 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-08.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing enzalutamide in Breast Neoplasms — 1 open to participants now, 3 under way, none of them phase 3. enzalutamide · Breast Neoplasms.
Among the 13 studies testing enzalutamide in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 1, and was the 1st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 13 studies testing enzalutamide in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 51st largest by enrollment of the 121 interventional ones that give a count, is one of 4 that started in 2012, is one of 37 in phase 1, and was the 65th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing enzalutamide in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02750358Memorial Sloan Kettering Cancer CenterFeasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | 2027-05 |
| NCT06099769Memorial Sloan Kettering Cancer CenterA Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing enzalutamide in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
enzalutamide be provided as two or four 40-mg capsules by mouth daily
Drug: enzalutamide
enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
Drug: anastrozole · Drug: enzalutamide
enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
Drug: exemestane · Drug: enzalutamide
enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
Drug: enzalutamide · Drug: exemestane
enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
Drug: fulvestrant · Drug: enzalutamide
80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
Also known as: MDV3100, Xtandi
1 mg/day
Also known as: Arimidex
The exemestane dose is 25mg daily.
Also known as: Aromasin
500 mg every 28 days
Also known as: Faslodex
160 mg (4 capsules) taken orally daily.
Also known as: MDV3100, Xtandi
The exemestane dose is 50 mg daily.
Also known as: Aromasin
Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs)
DLTs were defined as any of following events related to the study drug: Any adverse event (AE) consistent with a seizure of any grade; Grade greater than equal to (\>=) 3 fatigue, diarrhea, nausea, or vomiting that did not improve to Grade 1 within 14 days of initiating standard of care therapy; any Grade \>=3 hematologic toxicity with the following modifications: 1) Grade \>=3 platelet count associated with bleeding, 2) Grade \>=3 absolute neutrophil count that persists for 7 or more days or that was associated with fevers (febrile neutropenia); Grade \>=3 any other non-hematological toxicity that was determined to be related to study drug.
Time frame: Baseline up to Day 35
Percentage of Participants With Adverse Events of Grade 3 or Higher Severity by National Cancer Institute Common Toxicity Criteria For Adverse Events (NCI CTCAE) (Version 4.03)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on NCI CTCAE Version 4.03 and defined as Grade 3 AEs = severe or medically significant events but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living; Grade 4 AEs = life-threatening, urgent intervention indicated; Grade 5 AEs = death related to adverse event.
Time frame: Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years)
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years)
Percentage of Participants Who Discontinued the Study Drug Due to Adverse Events or Serious Adverse Events
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.
Time frame: Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years)
Percentage of Participants Who Require Dose Reductions Due to Adverse Events
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.
Time frame: Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years)
Percentage of Participants With Potentially Clinically Significant Change From Baseline in Vital Signs
Absolute systolic blood pressure (SBP) greater than (\>) 180 millimeter of mercury (mm Hg) and an increase of \>40 mm Hg from baseline; absolute SBP less than (\<) 90 mm Hg and an decrease of \>30 mm Hg from baseline. Absolute diastolic blood pressure (DBP) \>105 mm Hg and an increase of \>30 mm Hg from baseline; absolute DBP \<50 mm Hg and an increase of \>20 mm Hg from baseline. Absolute heart rate \>120 beats per minute (bpm) and an increase of \>30 bpm from baseline; absolute heart rate \<50 bpm and decrease of \>20 bpm from baseline. Participants with any of these abnormalities were reported for this outcome in each arm.
Time frame: Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years)
Dose-Escalation Phase: Maximum Plasma Concentration (Cmax) of Enzalutamide and Its Metabolites After Single Dose
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose-Escalation Phase: Time to Reach Maximum Plasma Concentration (Tmax) of Enzalutamide and Its Metabolites After Single Dosing
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose-Escalation Phase: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC24h) of Enzalutamide and Its Metabolites After Single Dose
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post dose on Day 1
Dose-Escalation Phase: Area Under the Plasma Concentration-time Curve From Time Zero to 72 Hours (AUC72h) of Enzalutamide After Single Dosing
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48 and 72 hours post dose on Day 1
Dose-Escalation Phase: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Enzalutamide After Single Dosing
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf).
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose-Escalation Phase: Terminal Elimination Half-Life (t1/2) of Enzalutamide After Single Dosing
Terminal elimination half-life is the time measured for the plasma concentration of Enzalutamide to decrease by one-half of its initial concentration.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose Escalation Phase: Apparent Oral Clearance (CL/F) of Enzalutamide After Single Dosing
Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose Escalation Phase: Apparent Volume of Distribution (Vz/F) of Enzalutamide After Single Dosing
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72 and 96 hours post dose on Day 1
Dose-Escalation Phase: Maximum Plasma Concentration (Cmax) of Enzalutamide and Its Metabolites After Multiple Dosing
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 50
Dose-Escalation Phase: Time to Reach Maximum Plasma Concentration (Tmax) of Enzalutamide and Its Metabolites After Multiple Dosing
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 50
Dose-Escalation Phase: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Enzalutamide and Its Metabolites After Multiple Dosing
Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 50
Dose-Escalation Phase: Apparent Oral Clearance (CL/F) of Enzalutamide After Multiple Dosing
Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 50
Dose-Escalation Phase: Peak-to-Trough Ratio of Enzalutamide and Its Metabolites After Multiple Dosing
Peak-to-trough ratio was calculated by dividing Cmax with Cmin of Enzalutamide and its Metabolites. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide. Cmax was maximum plasma concentration during the dosing interval and Cmin was minimum observed plasma concentration during the dosing interval.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 50
Dose-Escalation Phase: Accumulation Ratio of AUC24 of Enzalutamide and Its Metabolites After Multiple Dosing
Accumulation Ratio was defined as the ratio of AUC24 of Day 50 to AUC24 of Day 1, where AUC24 was area under the plasma concentration-time curve from time zero to 24 hours post-dose. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Day 1 and 50
Dose-Expansion Phase: Trough Plasma Concentration for Enzalutamide
Time frame: pre-dose on Day 57
| Milestone | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 14 | 20 | 16 | 23 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 14 | 20 | 16 | 23 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 | 3 | 0 |
| Withdrew: Disease progression | 0 | 0 | 14 | 18 | 14 | 18 | 11 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
DLTs were defined as any of following events related to the study drug: Any adverse event (AE) consistent with a seizure of any grade; Grade greater than equal to (\>=) 3 fatigue, diarrhea, nausea, or vomiting that did not improve to Grade 1 within 14 days of initiating standard of care therapy; any Grade \>=3 hematologic toxicity with the following modifications: 1) Grade \>=3 platelet count associated with bleeding, 2) Grade \>=3 absolute neutrophil count that persists for 7 or more days or that was associated with fevers (febrile neutropenia); Grade \>=3 any other non-hematological toxicity that was determined to be related to study drug.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs) | 16.7 | 0.0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on NCI CTCAE Version 4.03 and defined as Grade 3 AEs = severe or medically significant events but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living; Grade 4 AEs = life-threatening, urgent intervention indicated; Grade 5 AEs = death related to adverse event.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events of Grade 3 or Higher Severity by National Cancer Institute Common Toxicity Criteria For Adverse Events (NCI CTCAE) (Version 4.03) | 57.1 | 12.5 | 21.4 | 30.0 | 37.5 | 39.1 | 36.4 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) | 28.6 | 12.5 | 14.3 | 5.0 | 31.3 | 13.0 | 18.2 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Discontinued the Study Drug Due to Adverse Events or Serious Adverse Events | 0.0 | 0.0 | 7.1 | 5.0 | 12.5 | 13.0 | 0.0 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Require Dose Reductions Due to Adverse Events | 0.0 | 0.0 | 0.0 | 20.0 | 12.5 | 8.7 | 18.2 |
Absolute systolic blood pressure (SBP) greater than (\>) 180 millimeter of mercury (mm Hg) and an increase of \>40 mm Hg from baseline; absolute SBP less than (\<) 90 mm Hg and an decrease of \>30 mm Hg from baseline. Absolute diastolic blood pressure (DBP) \>105 mm Hg and an increase of \>30 mm Hg from baseline; absolute DBP \<50 mm Hg and an increase of \>20 mm Hg from baseline. Absolute heart rate \>120 beats per minute (bpm) and an increase of \>30 bpm from baseline; absolute heart rate \<50 bpm and decrease of \>20 bpm from baseline. Participants with any of these abnormalities were reported for this outcome in each arm.
| percentage of participants | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Blood pressure | 1 | 0 | 1 | 0 | 1 | 2 | 1 |
| Heart rate | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| micrograms per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 1.90 ± 0.757 | 4.01 ± 2.09 |
| M1 | 0.0375 ± 0.0286 | 0.0707 ± 0.0379 |
| M2 | 0.0879 ± 0.0718 | 0.184 ± 0.0689 |
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| hours | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 0.500 (0.500 to 2.00) | 1.00 (0.350 to 4.00) |
| M1 | 24.1 (5.55 to 25.1) | 23.1 (4.00 to 23.9) |
| M2 | 23.9 (21.1 to 25.1) | 23.7 (20.8 to 24.5) |
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| micrograms*hour per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 17.3 ± 8.32 | 41.6 ± 8.19 |
| M1 | 0.632 ± 0.385 | 1.20 ± 0.648 |
| M2 | 1.13 ± 0.916 | 2.76 ± 1.00 |
| micrograms*hour per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose-Escalation Phase: Area Under the Plasma Concentration-time Curve From Time Zero to 72 Hours (AUC72h) of Enzalutamide After Single Dosing | 43.0 ± 21.4 | 107 ± 15.6 |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf).
| micrograms*hour per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose-Escalation Phase: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Enzalutamide After Single Dosing | 208 ± 66.0 | 478 ± 232 |
Terminal elimination half-life is the time measured for the plasma concentration of Enzalutamide to decrease by one-half of its initial concentration.
| hours | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose-Escalation Phase: Terminal Elimination Half-Life (t1/2) of Enzalutamide After Single Dosing | 280 ± 170 | 198 ± 105 |
Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| liter per hour | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose Escalation Phase: Apparent Oral Clearance (CL/F) of Enzalutamide After Single Dosing | 0.426 ± 0.160 | 0.382 ± 0.115 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose Escalation Phase: Apparent Volume of Distribution (Vz/F) of Enzalutamide After Single Dosing | 151 ± 73.6 | 94.5 ± 13.7 |
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| micrograms per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 11.6 ± 1.95 | 15.3 ± 2.62 |
| M1 | 1.77 ± 0.521 | 6.24 ± 2.28 |
| M2 | 6.42 ± 0.132 | 14.1 ± 3.66 |
Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| hours | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 0.500 (0.00 to 5.50) | 1.00 (0.570 to 4.00) |
| M1 | 5.70 (0.500 to 24.0) | 2.29 (0.00 to 24.0) |
| M2 | 24.0 (0.570 to 24.0) | 0.58 (0.00 to 24.0) |
Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| milligram*hour per milliliter | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 207 ± 24.3 | 325 ± 61.6 |
| M1 | 33.0 ± 13.0 | 120 ± 56.0 |
| M2 | 140 ± 6.08 | 317 ± 89.4 |
Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| liter per hour | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Dose-Escalation Phase: Apparent Oral Clearance (CL/F) of Enzalutamide After Multiple Dosing | 0.390 ± 0.0491 | 0.507 ± 0.0906 |
Peak-to-trough ratio was calculated by dividing Cmax with Cmin of Enzalutamide and its Metabolites. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide. Cmax was maximum plasma concentration during the dosing interval and Cmin was minimum observed plasma concentration during the dosing interval.
| ratio | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 1.39 ± 0.400 | 1.14 ± 0.174 |
| M1 | 1.32 ± 0.407 | 1.42 ± 0.388 |
| M2 | 0.999 ± 0.0012 | 1.00 ± 0.0420 |
Accumulation Ratio was defined as the ratio of AUC24 of Day 50 to AUC24 of Day 1, where AUC24 was area under the plasma concentration-time curve from time zero to 24 hours post-dose. Carboxylic Acid (M1) and N-desmethyl (M2) are two metabolites of Enzalutamide.
| ratio | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg |
|---|---|---|
| Enzalutamide | 17.9 ± 2.69 | 9.39 ± 3.75 |
| M1 | 47.6 ± 21.4 | 68.0 ± 35.8 |
| M2 | 157 ± 48.2 | 77.8 ± 35.7 |
| micrograms per milliliter | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|
| Dose-Expansion Phase: Trough Plasma Concentration for Enzalutamide | 13.40 ± 2.51 | 14.33 ± 3.99 | 13.52 ± 2.62 | 12.41 ± 3.76 | 11.62 ± 4.69 |
Collected over Day 1 up to 30 days after the last dose of study drug or before initiation of a new systemic antitumor treatment, whichever occurred first (up to 3.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Enzalutamide 80 mg | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Dose Escalation: Enzalutamide 160 mg | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Dose Expansion: Enzalutamide 160 mg | 1/14 (7.1%) | 2/14 (14.3%) | 14/14 (100%) |
| Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | 0/20 (0%) | 1/20 (5%) | 20/20 (100%) |
| Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | 0/16 (0%) | 5/16 (31.3%) | 15/16 (93.8%) |
| Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | 0/23 (0%) | 3/23 (13%) | 21/23 (91.3%) |
| Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg | 0/11 (0%) | 2/11 (18.2%) | 11/11 (100%) |
| Event | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| Adrenal InsufficiencyEndocrine disorders | 1/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 0/11 |
| HydronephrosisRenal and urinary disorders | 1/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 0/11 |
| AnaemiaBlood and lymphatic system disorders | 0/7 | 1/8 | 0/14 | 0/20 | 0/16 | 0/23 | 0/11 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 0/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 1/11 |
| Gastritis ErosiveGastrointestinal disorders | 0/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 1/11 |
| Urinary Tract InfectionInfections and infestations | 0/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 0/7 | 0/8 | 0/14 | 0/20 | 0/16 | 0/23 | 1/11 |
| PneumoniaInfections and infestations | 0/7 | 0/8 | 0/14 | 0/20 | 0/16 | 2/23 | 0/11 |
| Abdominal PainGastrointestinal disorders | 0/7 | 0/8 | 1/14 | 0/20 | 0/16 | 0/23 | 0/11 |
| UrosepsisInfections and infestations | 0/7 | 0/8 | 1/14 | 0/20 | 0/16 | 0/23 | 0/11 |
| Event | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/7 | 2/8 | 8/14 | 12/20 | 8/16 | 12/23 | 8/11 |
| NauseaGastrointestinal disorders | 1/7 | 3/8 | 8/14 | 9/20 | 7/16 | 12/23 | 8/11 |
| Aspartate Aminotransferase IncreasedInvestigations | 4/7 | 1/8 | 0/14 | 2/20 | 1/16 | 0/23 | 0/11 |
| Back PainMusculoskeletal and connective tissue disorders | 0/7 | 1/8 | 5/14 | 3/20 | 2/16 | 5/23 | 6/11 |
| HypertensionVascular disorders | 1/7 | 4/8 | 1/14 | 1/20 | 0/16 | 5/23 | 2/11 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/7 | 1/8 | 1/14 | 10/20 | 5/16 | 4/23 | 2/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/7 | 4/8 | 2/14 | 3/20 | 3/16 | 4/23 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 3/7 | 1/8 | 2/14 | 6/20 | 4/16 | 3/23 | 4/11 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/7 | 3/8 | 0/14 | 1/20 | 3/16 | 2/23 | 1/11 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/7 | 3/8 | 0/14 | 0/20 | 0/16 | 0/23 | 0/11 |
Safety analysis population included all enrolled participants who received at least 1 dose of Enzalutamide.
| Age, Customized(Participants) | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Less than (<) 65 years | 6 | 5 | 11 | 12 | 13 | 10 | 6 | 63 |
| Between 65 to 74 years | 1 | 3 | 2 | 5 | 2 | 12 | 4 | 29 |
| Greater than or equal to (>=) 75 years | 0 | 0 | 1 | 3 | 1 | 1 | 1 | 7 |
| Sex: Female, Male(Participants) | Dose Escalation: Enzalutamide 80 mg | Dose Escalation: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg | Dose Expansion: Enzalutamide 160 mg + Anastrozole 1 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 25 mg | Dose Expansion: Enzalutamide 160 mg + Exemestane 50 mg | Dose Expansion: Enzalutamide 160 mg + Fulvestrant 500 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 8 | 14 | 20 | 16 | 23 | 11 | 99 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
No publications or documents are linked to this record.
Ran from Apr 2012 to primary completion in Dec 2015, 43 months.
Results were first posted in May 2019, 3 years 4 months after primary completion.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 43 months is above that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide